Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies

USA - English

• India - English

PUNE, India, January 28, 2016 /PRNewswire/ --

New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company Profiles discussed in this report includes Actelion Ltd, Akari Therapeutics, Plc, Alaxia SAS, AlgiPharma AS, AmpliPhi Biosciences Corporation, Arcturus Therapeutics, Inc, Aridis Pharmaceuticals LLC, Bayer AG, Boehringer Ingelheim GmbH, Carolus Therapeutics, Inc., Celtaxsys, Inc., Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals, Inc., Corbus pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc., DiscoveryBiomed, Inc., Errant Gene Therapeutics, LLC, Galapagos NV, GlaxoSmithKline Plc, Grifols, S.A., Grupo Praxis Pharmaceutical SA, Horizon Pharma Plc, Insmed Incorporated, Invion Limited, JHL Biotech, Inc., Kamada Ltd., La Jolla Pharmaceutical Company, Lamellar Biomedical Ltd, Laurent Pharmaceuticals Inc., Merck & Co., Inc., Microbion Corporation, Mucokinetica Ltd., NanoBio Corporation, Nivalis Therapeutics, Inc., Nostrum Pharmaceuticals LLC, Novabiotics Limited, Novartis AG, OSE Pharma SA, Parion Sciences, Inc., Pfizer Inc., Pharmaxis Limited, PhaseBio Pharmaceuticals, Inc., Polyphor Ltd., Progenra, Inc., ProQR Therapeutics N.V., Protalix BioTherapeutics, Inc., Proteostasis Therapeutics, Inc., PTC Therapeutics, Inc., Pulmatrix, Inc., ReveraGen BioPharma, Inc., Savara Inc., Serendex Pharmaceuticals A/S, Shionogi & Co., Ltd., Shire Plc, Synovo GmbH, TGV-Laboratories, The International Biotechnology Center (IBC) Generium, Verona Pharma Plc, Vertex Pharmaceuticals Incorporated, Xenetic Biosciences plc and Zambon Company S.p.A.

Complete report on H2 2015 pipeline review of Cystic Fibrosis with 98 market data tables and 17 figures, spread across 368 pages is available at http://www.reportsnreports.com/reports/461977-cystic-fibrosis-pipeline-review-h2-2015.html .

Drugs Profiles discussed in this report includes (ammonium chloride + citric acid + sodium citrate), (fosfomycin + tobramycin), (lumacaftor + ivacaftor), (tezacaftor + ivacaftor), ABPA-01, acebilustat, Aerucin, alpha-1 proteinase inhibitor (human) second generation, ALX-009, amikacin sulphate, amlexanox, Anti-Pseudomonas IgY, Antimicrobial Drug for Cystic Fibrosis, AT-010, ataluren, Biologics for Cystic Fibrosis Lung Infections, budesonide, Calcaftor, CFX-1, CSY-0073, CT-2009, CTP-656, cysteamine IR, dapsone, Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis, doripenem, dornase alfa biosimilar, dornase alfa biosimilar, Drug for Cystic Fibrosis, FDL-169, fenretinide, Gene Therapy to Activate CFTR for Cystic Fibrosis, Gene Therapy to Activate CFTR Gene for Cystic Fibrosis, GLPG-1837, GLPG-2222, GLPG-2665, glycerol phenylbutyrate, GSK-2225745, JBT-101, kenpaullone, levofloxacin, LJPC-30Sa, LJPC-30Sb, LMS-611, LUNAR-CF, mannitol, MG-277, miglustat, MKA-104, molgramostim, Mul-1867, N-91115, N-91138, N-91169, nadolol, NB-401, nitric oxide, nitric oxide, NVPQBE-170, Oligomer G for Cystic Fibrosis, ORP-100, P-1055, Panaecin, PB-01, PB-1046, PB-1120, Peptide to Block ENaC for Cystic Fibrosis and Hypertension, POL-6014, PRX-110, Pseudomonas aeruginosa vaccine, PTI-130, PTI-428, PTIC-1811, PTIP-271, PulmoXen, PUR-1900, PXS-4728A, QBW-251, QBW-276, QR-010, QR-X4, Recombinant A1PI, Recombinant Enzyme to Replace Acid Ceramidase for Farber Disease and Cystic Fibrosis, Recombinant Enzyme to Target DNA for Cystic Fibrosis, Recombinant Protein for Infectious Diseases and Respiratory Disorders, riociguat, RPL-554, S-1226, S-1229, S-18, seliciclib, SHP-636, Small Molecule for Cystic Fibrosis, Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis, Small Molecule to Activate CFTR for Cystic Fibrosis, Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease, Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD, Small Molecules for Bacterial Infections, Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis, Small Molecules for Cystic Fibrosis, Small Molecules to Activate CFTR for Cystic Fibrosis, Small Molecules to Activate CFTR Protein for Cystic Fibrosis, Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis, Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis, Small Molecules to Inhibit Sodium Channels for Cystic Fibrosis, Small Molecules to Inhibit USP8 for Cystic Fibrosis, solithromycin, SP-14, SP-9, Stem Cell Therapy for Cystic Fibrosis, SYGN-113, SYGN-303, tritoqualine, vancomycin hydrochloride, Verolone, VX-152, VX-371, VX-440 and ZP-046.

Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=461977 .

The report reviews key pipeline products under drug profile section and key players involved in the therapeutics development for Cystic Fibrosis with their major and minor projects summarizing all the dormant and discontinued pipeline projects.

Explore more reports on Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http: //http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]

SOURCE ReportsnReports